Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) has received an average rating of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target […]

Apr 30, 2025 - 07:11

Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) has received an average rating of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target […]